Answers are grounded in this paper and cite their sources.
Randomized trial develops new PI3Kγ inhibitors through advanced computational drug design methods, suggesting effectiveness.
Introduction: Phosphoinositide-3-kinase gamma (PI3Kγ) has emerged as a valuable therapeutic target for various diseases. However, there is a notable scarcity of inhibitors that have advanced to clinical studies, highlighting the urgent need for the development of novel PI3Kγ inhibitors. Methods: A three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis was conducted to investigate the structure-activity relationships of PI3Kγ inhibitors. A scaffold growth strategy was employed to design novel compounds. Furthermore, a virtual screening workflow integrating drug-likeness filtering, 3D-QSAR predictions, and molecular docking was established. Results: An optimal CoMFA model was developed with q² = 0.752, r² = 0.995, and r²pred = 0.736, revealing key structural features and interactions crucial for selective PI3Kγ inhibition. Using the N-phenyl isoquinolinone core of IPI-549 as a template, new compounds were generated via a reaction-based scaffold growth approach. Following drug-likeness evaluation, 3DQSAR predictions, and molecular docking, nine compounds demonstrated superior predicted activity compared to IPI-549. Three top-ranked hits were subsequently subjected to molecular dynamics simulations and binding free energy calculations, providing insights into the PI3Kγ/Hit binding mechanism and identifying critical residues governing selectivity, including MET804, TRP812, ILE831, VAL882, and MET953. Discussion: Developing selective PI3Kγ inhibitors is challenging due to the high homology among kinase structures. IPI-549, the first PI3Kγ inhibitor to enter clinical trials, served as a suitable template for designing novel selective inhibitors. This study applied computer-aided drug design strategies to formulate promising new PI3Kγ inhibitors. Conclusion: The present workflow provides an effective and precise approach for identifying novel PI3Kγ inhibitors and offers valuable guidance for the rational design of selective PI3Kγ- targeted therapeutics.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: